OAM
CBIO

Oxford Asset Management’s Crescent Biopharma CBIO Stock Holding History

Oxford Asset Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,330
Closed -$704K – 644
2019
Q4 		$704K Buy
+1,330
New +$720K 0.02% 1055

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oxford Asset Management's CBIO Position: Q1 2020 in Review

Oxford Asset Management sold out of Crescent Biopharma (CBIO) in Q1 2020, closing a stake of 1,330 shares — an estimated $704K sold.

Oxford Asset Management first reported a position in CBIO in Q4 2019 and held it in 1 quarter. The position peaked at $704K in Q4 2019. 76 funds tracked by Wall St. Rank hold CBIO as of Q1 2020.

  • Oxford Asset Management reported no remaining Crescent Biopharma position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 1,330 Crescent Biopharma shares in Q1 2020, an estimated $704K.
  • Oxford Asset Management first reported a position in Crescent Biopharma in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's Crescent Biopharma position peaked at $704K in Q4 2019.
  • 76 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.